RxDoctor Payments Data

Nasser Hambaz, MD

Family Medicine · Virginia Beach, VANPI 1174533129

Payments from drug & device makers

$14,420in general payments, 2019–2025

Across 726 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • GSK$1K
  • Novo Nordisk$1K
  • Amgen$945
  • Boehringer Ingelheim$944
  • Lilly USA, LLC$841
  • plus $6K from 44 others

What the payments were for

  • Food & beverage$14,32499%
  • Education$971%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,420 in reported general payments places this provider in the 95th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$159,138
Medicare patients
245
Services billed
1,826

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol85$112,102
OzempicSemaglutide106$110,702
EliquisApixaban49$59,706
MounjaroTirzepatide50$55,959
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$50,844
JardianceEmpagliflozin24$32,197
JanuviaSitagliptin Phosphate22$31,886
TrulicityDulaglutide12$31,543
XareltoRivaroxaban28$27,525
Breztri AerosphereBudesonide/Glycopyr/Formoterol31$26,510
TradjentaLinagliptin16$24,305
JanumetSitagliptin Phos/Metformin Hcl22$17,701
Spiriva RespimatTiotropium Bromide18$14,533
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$10,139
LinzessLinaclotide12$8,640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$3,178$142,514132 claims
Novo NordiskOzempic$1,013$110,702106 claims
Lilly USA, LLCMounjaro, Trulicity$841$87,50162 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Stiolto Respimat$944$81,17473 claims
PfizerEliquis, Premarin$681$63,45263 claims
GSKTrelegy Ellipta$1,301$50,84465 claims
MerckJanuvia, Janumet$132$49,58644 claims
Johnson & JohnsonXarelto$212$27,52528 claims
AbbVieLinzess, Synthroid$449$10,82041 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →